Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs.

This study provides compelling evidence that a novel endoluminal device can offer superior metabolic benefits compared to a leading GLP-1 receptor agonist like semaglutide in an obese pig model. The significant improvements in both weight control and insulin sensitivity suggest a potent therapeutic mechanism, potentially involving direct modulation of gut hormones or nutrient sensing.

Written by TitrateLab, separately from the study summarized above.